How volatile is AbbVie Inc.?

Over the past year, AbbVie Inc. had an annualised volatility of 25.45%, based on daily closes. Its deepest fall from a high in that time was 16.46%, from November 21, 2025 to April 27, 2026. Its beta against the S&P 500 was -0.14.

What was the biggest price drop for AbbVie Inc.?

The deepest fall in our weekly price history since December 2012 was 47.27%, from a high in the week of January 22, 2018 to a low in the week of March 16, 2020. The price regained that high in the week of December 6, 2021.

Which month has historically been best for AbbVie Inc.?

Since 2015, February has had the highest average return for AbbVie Inc. (+4.54%, up in 10 of 12 years) and March the lowest (-1.84%, up in 6 of 12 years). Past seasonal patterns do not predict future returns.

stock · yahoo

AbbVie Inc.

ABBV

$294.89

▲ 4.1 (1.41%)

polled

Below: live stock price for AbbVie Inc. (ABBV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

AbbVie Inc. (ABBV) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 57,000 people. Over the past year ABBV traded between 190.75 and 298.74 USD. Trailing P/E sits near 83.3 on a market cap of about 521.11B USD. It currently yields 2.35% in dividends.

Day

+1.41%

+4.10

Week

+3.24%

+9.25

Month

+13.45%

+34.96

Year

+35.25%

+76.85

Prev close: $290.79
Volume (24h): $2.03B
Market cap: $521.11B
Currency: USD

Score

62/ 100 · Solid

Coverage: 6/7

Value48
Quality82
Momentum59
Growth72
Risk96
Dividend15
Liquidity—

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 78%Pace +0.24% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 297.6553
+20 bars: 301.5134
+60 bars: 303.0193
+120 bars: 303.0747

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.26% per bar.

Interpretation

Composite signals look solid. Strength: risk profile with weakness: dividend. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
48/100
Value looks mixed — driven by P/E (83.3).
P/E:83.3PEG:0.6
Quality
82/100
Quality looks strong — driven by Gross margin (75.01%).
Profit margin:15.67%Gross margin:75.01%
Momentum
59/100
Momentum looks mixed — driven by 52w change (39.13%).
52w change:39.13%
Growth
72/100
Growth looks solid — driven by Earnings growth (2282.10%).
Revenue growth:10.30%Earnings growth:2282.10%
Risk
96/100
Risk looks strong — driven by Short interest (0.98%).
Short interest:0.98%
Dividend
15/100
Dividend looks fragile — driven by Payout ratio (190.40%).
Dividend yield:2.35%Payout ratio:190.40%

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 251 days.

Position in range96%

190.75 low298.74 high

Where the price sits between the window low and high.

Volatility (annualised): 25.5%
Max drawdown: -16.5%
Below period high: -1.3%
Best day: +6.25%
Worst day: -5.20%
Up days: 52%
Current streak: 2 up
Typical day swing: 2.4%
Volume vs average: -8%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

314.1869 USD+6.54%

Fib +27.2% extension

Next level below

285.3376 USD-3.24%

Fib 23.6% retracement

Levels derived from: 298.74 high → 241.95 low · 60 bars

Resistance
Fib +161.8% extension
not reached
390.6262 USD
+32.47% from current
Resistance
Fib +100% extension
not reached
355.53 USD
+20.56% from current
Resistance
Fib +61.8% extension
not reached
333.8362 USD
+13.21% from current
Resistance
Fib +27.2% extension
not reached
314.1869 USD
+6.54% from current
Current
294.89 USD
Support
Fib 23.6% retracementNearest
tested 11×
285.3376 USD
-3.24% from current
Support
Fib 38.2% retracement
tested 4×
277.0462 USD
-6.05% from current
Support
Fib 50% midpoint
tested 2×
270.345 USD
-8.32% from current
Support
Fib 61.8% retracement
tested 23×
263.6438 USD
-10.60% from current
Support
Fib 78.6% retracement
tested 6×
254.1031 USD
-13.83% from current
Support
Fib −27.2% extension
not reached
226.5031 USD
-23.19% from current
Support
Fib −61.8% extension
not reached
206.8538 USD
-29.85% from current
Support
Fib −100% extension
not reached
185.16 USD
-37.21% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $298.74
52w low: $190.75
52w change: 39.13%
Day high: $298.74
Day low: $291.01
P/E (TTM): 83.3
Forward P/E: 18.2
PEG: 0.6
EPS (TTM): $3.54
Forward EPS: $16.20
Dividend yield: 2.35%
Dividend rate: $6.92
Payout ratio: 190.40%
Revenue (TTM): 66.01B
EBITDA: 32.41B
Profit margin: 15.67%
Gross margin: 75.01%
Shares outstanding: 1.77B
Float: 1.77B

Sector: HealthcareIndustry: Drug Manufacturers - GeneralHQ: United StatesEmployees: 57Kwww.abbvie.com

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Analyst & Risk

Consensus

Analysts' consensus via Yahoo Finance — not investment advice.

Analysts: positive

Mean rating1.69 / 5

Analysts27

Next earnings2026-10-30

Very positive: 7Positive: 16Neutral: 5Very negative: 1

Analyst price target

$283.19

Mean target · 27 analysts

-4.0%

mean target vs. price

Low $200.00Now $294.89High $325.00

52-week change: 39.13%
Short % of float: 0.98%
Short ratio (days): 3.22
PEG ratio: 0.6
Revenue growth: 10.30%
Earnings growth: 2282.10%
EBITDA: 32.41B
Insider holdings: 0.11%
Institutional: 77.39%

Recent rating changes

2026-10-23Goldman SachsNeutral → Neutralmain
2026-10-21BarclaysOverweight → Overweightmain
2026-10-13RBC CapitalOutperform → Outperformreit
2026-10-09UBSNeutral → Neutralmain
2026-10-09GuggenheimBuy → Buyreit
2026-10-08JP MorganOverweight → Overweightmain
2026-10-08Cantor FitzgeraldOverweight → Overweightmain
2026-10-07Morgan StanleyOverweight → Overweightmain

Financial documents

AbbVie Inc. performance

Change from the closing price at the start of each period to the latest price.

Period	Start price	Change	Per year
1 week$285.64	$285.64	+3.24%
1 month$261.59	$261.59	+12.73%
3 months$250.94	$250.94	+17.51%
6 months$211.32	$211.32	+39.55%
Year to date$228.49	$228.49	+29.06%
1 year$218.04	$218.04	+35.25%
3 years$141.89	$141.89	+107.8%	+27.48%
5 years$114.81	$114.81	+156.9%	+20.74%
10 years$55.78	$55.78	+428.7%	+18.10%
Since Dec 2012$34.46	$34.46	+755.7%	+16.80%

Periods up to a year use daily closes, longer ones weekly closes. “Per year” is the compound annual growth rate.

Price change only; dividends are not included.

AbbVie Inc. all-time high and low

All-time high

$298.74

Oct 30, 2026

1.29% below the high

All-time low

$33.33

week of Jan 7, 2013

784.8% above the low

52-week range

96%

Low

$190.75

Apr 29, 2026

High

$298.74

Oct 30, 2026

The latest price sits at 96% of this range.

Highs and lows include intraday prices.

AbbVie Inc. risk metrics

Past year of daily closes unless stated otherwise.

Volatility (1 year, annualised): 25.45%; How large price swings have been: the standard deviation of daily returns, scaled up to a year.
Max drawdown (1 year): -16.46%; Nov 21, 2025 → Apr 27, 2026 · Recovered on Jun 25, 2026.; The deepest fall from a previous high to a later low over the past year.
Max drawdown (since Dec 2012): -47.27%; Jan 2018 → Mar 2020 · Recovered in the week of Dec 6, 2021.; The same measure across the whole weekly price history.
Sharpe ratio (risk-free rate 0): 1.32; Average daily return divided by its volatility, annualised: higher means more return for each unit of risk over the past year.
Beta vs S&P 500 (1 year): -0.14; On average, AbbVie Inc. moved -0.14% for each 1% move in the S&P 500 on the same day.

AbbVie Inc. drawdown from peak

How far the price stood below its previous high, based on weekly closes since Dec 2012.

AbbVie Inc. seasonality

Monthly returns by year, from month-end closes: daily data for the past year, weekly closes before that.

AbbVie Inc. seasonality
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.4%	+4.1%	-6.3%	-2.8%	+3.0%	+16%	-0.3%	+2.2%	+2.0%	+13%*			+29%*
2025	+7.9%	+11%	-0.9%

AbbVie Inc. price history

Yearly open, high, low and close, newest first.

AbbVie Inc. price history
Year	Open	High	Low	Close	Change
2026YTD	$228.74	$298.74	$190.75	$294.89	+29.06%
2025	$176.35	$244.81	$164.39	$228.49	+29.68%
2024	$154.90	$207.32	$153.58	$176.20	+13.70%
2023	$162.04	$168.11	$130.96	$154.97	-4.11%
2022	$135.33	$175.91	$128.26	$161.61	+19.34%

Frequently asked questions about AbbVie Inc.

What is the price of AbbVie Inc. today?

As of October 31, 2026, the price of AbbVie Inc. is $294.89, up 1.41% from the previous close.

What is the all-time high of AbbVie Inc.?

The all-time high of AbbVie Inc. is $298.74, reached on October 30, 2026. At $294.89, the latest price is 1.29% below that peak.

How much has AbbVie Inc. gained this year?

AbbVie Inc. is up 29.06% so far in 2026: it closed 2025 at $228.49 and is at $294.89 now.

Calculated from historical closing prices — daily for the past year, weekly before that — and refreshed as new prices arrive. Past performance does not predict future returns. Not investment advice.


Average	-1.2%	+4.5%	-1.8%	+0.3%	+0.1%	+2.4%	+1.1%	+1.1%	+0.7%	+1.1%	+4.4%	+2.7%	+13%
Years up	33%	83%	50%	50%	50%	50%	50%	50%	58%	64%	82%	73%	64%

Year	Open	High	Low	Close	Change
2021	$105.41	$136.83	$101.81	$135.42	+28.47%
2020	$88.21	$109.15	$62.55	$105.41	+19.08%
2019	$91.24	$92.30	$62.66	$88.52	-3.98%
2018	$97.14	$125.86	$77.50	$92.19	-4.67%
2017	$62.92	$99.10	$59.27	$96.71	+54.44%
2016	$57.99	$68.12	$50.71	$62.62	+8.70%
2015	$66.77	$71.60	$45.45	$57.61	-14.19%
2014	$52.99	$70.76	$45.50	$67.14	+26.66%
2013	$34.92	$54.78	$33.33	$53.01	—

Month	Close	Change
September 2026	$261.59	+2.02%
August 2026	$256.42	+2.18%
July 2026	$250.94	-0.28%
June 2026	$251.64	+15.58%
May 2026	$217.72	+3.03%
April 2026	$211.32	-2.84%

Month	Close	Change
March 2026	$217.49	-6.29%
February 2026	$232.08	+4.07%
January 2026	$223.01	-2.40%
December 2025	$228.49	+0.35%
November 2025	$227.70	+4.43%
October 2025	$218.04	-2.29%

AbbVie Inc.

Financials

Analyst & Risk

Recent rating changes

Financial documents

AbbVie Inc. performance

AbbVie Inc. all-time high and low

52-week range

AbbVie Inc. risk metrics

AbbVie Inc. drawdown from peak

AbbVie Inc. seasonality

AbbVie Inc. price history

Frequently asked questions about AbbVie Inc.

What is the price of AbbVie Inc. today?

What is the all-time high of AbbVie Inc.?

How much has AbbVie Inc. gained this year?

Recent news

Learn the terms

Live discussion

AbbVie Inc. performance

AbbVie Inc. all-time high and low

52-week range

AbbVie Inc. risk metrics

AbbVie Inc. drawdown from peak

AbbVie Inc. seasonality

AbbVie Inc. price history

Frequently asked questions about AbbVie Inc.

What is the price of AbbVie Inc. today?

What is the all-time high of AbbVie Inc.?

How much has AbbVie Inc. gained this year?

AbbVie Inc. month-end closes

How volatile is AbbVie Inc.?

What was the biggest price drop for AbbVie Inc.?

Which month has historically been best for AbbVie Inc.?